{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:08:29Z","timestamp":1786993709164,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Western Pacific"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.lanwpc.2021.100128","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T06:07:28Z","timestamp":1616479648000},"page":"100128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Effectiveness and safety of iguratimod treatment in patients with active rheumatoid arthritis in Chinese: A nationwide, prospective real-world study"],"prefix":"10.1016","volume":"10","author":[{"given":"Rong","family":"Mu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenbiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lie","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanguo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.lanwpc.2021.100128_bib0001","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.lanwpc.2021.100128_bib0002","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s10067-017-3850-z","article-title":"Remission assessment of rheumatoid arthritis in daily practice in China: a cross-sectional observational study","volume":"37","author":"Zhu","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.lanwpc.2021.100128_bib0003","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000993","article-title":"Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift","volume":"5","author":"Chatzidionysiou","year":"2019","journal-title":"RMD Open"},{"issue":"8","key":"10.1016\/j.lanwpc.2021.100128_bib0004","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1111\/1756-185X.13028","article-title":"Burden of rheumatoid arthritis from a societal perspective: a prevalence-based study on cost of this illness for patients in China","volume":"21","author":"Hu","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.lanwpc.2021.100128_bib0005","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41413-019-0067-6","article-title":"Iguratimod: a valuable remedy from the Asia Pacific region for ameliorating autoimmune diseases and protecting bone physiology","volume":"7","author":"Li","year":"2019","journal-title":"Bone Res"},{"issue":"11","key":"10.1016\/j.lanwpc.2021.100128_bib0006","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1248\/bpb1978.15.649","article-title":"Pharmacological studies on 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (T-614), a novel antiinflammatory agent. 4th communication: inhibitory effect on the production of interleukin-1 and interleukin-6","volume":"15","author":"Tanaka","year":"1992","journal-title":"J Pharmacobiodyn"},{"issue":"4","key":"10.1016\/j.lanwpc.2021.100128_bib0007","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1254\/jjp.67.305","article-title":"T-614, a novel antirheumatic drug, inhibits both the activity and induction of cyclooxygenase-2 (COX-2) in cultured fibroblasts","volume":"67","author":"Tanaka","year":"1995","journal-title":"Jpn J Pharmacol"},{"issue":"11","key":"10.1016\/j.lanwpc.2021.100128_bib0008","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/rheumatology\/keg381","article-title":"Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice","volume":"42","author":"Tanaka","year":"2003","journal-title":"Rheumatology"},{"issue":"12","key":"10.1016\/j.lanwpc.2021.100128_bib0009","first-page":"2591","article-title":"Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells","volume":"28","author":"Kohno","year":"2001","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.lanwpc.2021.100128_bib0010","doi-asserted-by":"crossref","first-page":"R136","DOI":"10.1186\/ar2554","article-title":"T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis","volume":"10","author":"Du","year":"2008","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"10.1016\/j.lanwpc.2021.100128_bib0011","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.4049\/jimmunol.1300832","article-title":"A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide","volume":"191","author":"Luo","year":"2013","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.lanwpc.2021.100128_bib0012","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.intimp.2012.03.003","article-title":"T-614 alters the production of matrix metalloproteinases (MMP-1 andMMP-3) and inhibits the migratory expansion of rheumatoid synovial fibroblasts, in vitro","volume":"13","author":"Du","year":"2012","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"10.1016\/j.lanwpc.2021.100128_bib0013","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/00029330-200804010-00008","article-title":"Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial","volume":"121","author":"L\u00fc","year":"2008","journal-title":"Chin Med J"},{"issue":"7","key":"10.1016\/j.lanwpc.2021.100128_bib0014","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/art.24643","article-title":"Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate","volume":"61","author":"Lu","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.lanwpc.2021.100128_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/s10165-006-0542-y","article-title":"Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study","volume":"17","author":"Hara","year":"2007","journal-title":"Mod Rheumatol"},{"issue":"3","key":"10.1016\/j.lanwpc.2021.100128_bib0016","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3109\/s10165-012-0724-8","article-title":"Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial","volume":"23","author":"Ishiguro","year":"2013","journal-title":"Mod Rheumatol"},{"issue":"3","key":"10.1016\/j.lanwpc.2021.100128_bib0017","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3109\/14397595.2013.843756","article-title":"Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial","volume":"24","author":"Hara","year":"2014","journal-title":"Mod Rheumatol"},{"issue":"9","key":"10.1016\/j.lanwpc.2021.100128_bib0018","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s10067-015-2999-6","article-title":"Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial","volume":"34","author":"Duan","year":"2015","journal-title":"Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.lanwpc.2021.100128_bib0019","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s00393-015-1641-y","article-title":"Iguratimod in combination with methotrexate in active rheumatoid arthritis: therapeutic effects","volume":"75","author":"Xia","year":"2016","journal-title":"Z Rheumatol"},{"issue":"2","key":"10.1016\/j.lanwpc.2021.100128_bib0020","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/14397595.2014.938401","article-title":"Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis","volume":"25","author":"Okamura","year":"2015","journal-title":"Mod Rheumatol"},{"issue":"12","key":"10.1016\/j.lanwpc.2021.100128_bib0021","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/acr.21762","article-title":"Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of North America cohort of rheumatoid arthritis patients","volume":"64","author":"Jawaheer","year":"2012","journal-title":"Arthritis Care Res"},{"issue":"9","key":"10.1016\/j.lanwpc.2021.100128_bib0022","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1007\/s00296-011-2033-5","article-title":"Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study","volume":"32","author":"Kleinert","year":"2012","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.lanwpc.2021.100128_bib0023","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/art.23247","article-title":"Clinical remission and\/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study","volume":"59","author":"Burmester","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.lanwpc.2021.100128_bib0024","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1002\/art.23141","article-title":"Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis","volume":"56","author":"van der Heijde","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.lanwpc.2021.100128_bib0025","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3899\/jrheum.110610","article-title":"Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British society for rheumatology biologics register","volume":"39","author":"Soliman","year":"2012","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.lanwpc.2021.100128_bib0026","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1002\/art.22640","article-title":"A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis","volume":"56","author":"Wessels","year":"2007","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.lanwpc.2021.100128_bib0027","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/ard.62.5.423","article-title":"Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis","volume":"62","author":"Hoekstra","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.lanwpc.2021.100128_bib0028","first-page":"11","article-title":"Factors influencing response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis","volume":"32","author":"Hider","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.lanwpc.2021.100128_bib0029","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12891-016-1038-3","article-title":"The challenging interplay between rheumatoid arthritis, ageing and comorbidities","volume":"17","author":"van Onna","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"issue":"9","key":"10.1016\/j.lanwpc.2021.100128_bib0030","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1136\/ard.2005.037903","article-title":"Impact of age and comorbidities on the criteria for remission and response in rheumatoid arthritis","volume":"64","author":"Krishnan","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.lanwpc.2021.100128_bib0031","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/1759720X15612250","article-title":"Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review","volume":"7","author":"Iqbal","year":"2015","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"2","key":"10.1016\/j.lanwpc.2021.100128_bib0032","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1080\/14397595.2018.1460230","article-title":"Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: final report of a 52-week, multicenter postmarketing surveillance study","volume":"29","author":"Mimori","year":"2019","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.lanwpc.2021.100128_bib0033","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/310628","article-title":"Efficacy and safety of iguratimod for the treatment of rheumatoid arthritis","volume":"2013","author":"Li","year":"2013","journal-title":"Clin Dev Immunol"},{"issue":"3","key":"10.1016\/j.lanwpc.2021.100128_bib0034","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1080\/14397595.2018.1481565","article-title":"Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF-\u03baB and production of RANKL: its efficacy, radiographic changes, safety and predictors over two years' treatment for Japanese rheumatoid arthritis patients","volume":"29","author":"Ishikawa","year":"2019","journal-title":"Mod Rheumatol"},{"issue":"5","key":"10.1016\/j.lanwpc.2021.100128_bib0035","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/14397595.2016.1265695","article-title":"Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan","volume":"27","author":"Mimori","year":"2017","journal-title":"Mod Rheumatol"}],"container-title":["The Lancet Regional Health - Western Pacific"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666606521000377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666606521000377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:34:34Z","timestamp":1763001274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666606521000377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":35,"alternative-id":["S2666606521000377"],"URL":"https:\/\/doi.org\/10.1016\/j.lanwpc.2021.100128","relation":{},"ISSN":["2666-6065"],"issn-type":[{"value":"2666-6065","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of iguratimod treatment in patients with active rheumatoid arthritis in Chinese: A nationwide, prospective real-world study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Western Pacific","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanwpc.2021.100128","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100128"}}